The GeneCellNano Flagship develops new effective therapies for severe chronic diseases.
GeneCellNano focuses on innovation and commercial development associated with biological drugs, biomarkers and diagnostics. Participating in the Flagship are leading Finnish researchers specialised in gene, cell and nano therapies as well as clinical operators, leading businesses and the third sector.
In the context of GeneCellNano, the University of Helsinki aims to specifically develop therapies based on genes, liposomes, nanoparticles and extracellular vesicles.
The GeneCellNano Flagship is coordinated by the University of Eastern Finland, and the University of Helsinki is a partner in it along with Oulu University, Aalto University and the Blood Service of the Finnish Red Cross.
The iCAN Digital Precision Cancer Medicine Flagship promotes the development of personalised cancer treatments and health-related innovations.
The iCAN Flagship links precision medicine in a novel way to patients’ digital health and lifestyle data. Its research and development activities make use of Finland’s unique health registers and digital healthcare system. Data mining from these is being developed with the help of, for example, artificial intelligence.
The goal of iCAN is to generate breakthroughs in research and to develop research-based innovations that help improve cancer treatment and the quality of life of cancer patients. Patients and patient organisations are actively involved in planning research and developing activities in the context of the Flagship.
The University of Helsinki and the Hospital District of Helsinki and Uusimaa (HUS) jointly coordinate iCAN.
Kari Alitalo, Academy Professor, is the director of the iCAN Flagship.